Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 2/20 | 0.50 |
| ▸ | UBE2M | P61081 | 1/20 | 0.50 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 3/20 | 0.48 |
| ▸ | SCN4A | P35499 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7225533 | 1.00 | CYP2D6 (0.53) | CYP2D6CYP2C19ACHEUBE2MDCUN1D1 | |
| SCHEMBL7225784 | 1.00 | CYP2D6 (0.53) | CYP2D6CYP2C19ACHEUBE2MDCUN1D1 | |
| SCHEMBL7225251 | 1.00 | CYP2D6 (0.53) | CYP2D6CYP2C19ACHEUBE2MDCUN1D1 | |
| SCHEMBL7225790 | 1.00 | CYP2D6 (0.53) | CYP2D6CYP2C19ACHEUBE2MDCUN1D1 | |
| SCHEMBL15866139 | 0.88 | S1PR5 (0.48) | ACHEUBE2MDCUN1D1BCHEMAOB | |
| SCHEMBL27841299 | 0.88 | S1PR5 (0.48) | ACHEUBE2MDCUN1D1BCHEMAOB | |
| SCHEMBL10713365 | 0.88 | BCHE (0.46) | ACHEBCHESCN4AMAOB | |
| SCHEMBL7226639 | 0.87 | CYP2D6 (0.43) | CYP2D6CYP2C19ACHEUBE2MDCUN1D1 | |
| SCHEMBL915350 | 0.86 | ACHE (0.47) | ACHEBCHESCN4AMAOB | |
| SCHEMBL915351 | 0.86 | ACHE (0.47) | ACHEBCHESCN4AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6608078-B2 | Gramnegative bacteria | WOCKHARDT LIMITED (IN) | 2003-08-19 | — | — | US | disclosed |
| US-20020165227-A1 | Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment | WOCKHARDT RESEARCH CENTER | 2002-11-07 | — | — | US | disclosed |
| WO-2001085728-A2 | ANTIBACTERIAL CHIRAL 8-(SUBSTITUTED PIPERIDINO)-BENZO [I, J] QUINOLIZINES, PROCESSES, COMPOSITIONS AND METHODS OF TREATMENT | WOCKHARDT LIMITED (IN) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165227-A1 | Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment | ALPI, POLR1C, POLI | CYP2D6 121/4885CYP2C19 75/4885ACHE 2557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.